Skip to main content
. 2016 Dec 28;140(1):201–217. doi: 10.1093/brain/aww271

Figure 3.

Figure 3

Intranasal hNGFp, but not BDNF, decreases amyloid-β plaque load in 5xFAD mice. (A) Scheme of intranasal delivery to 5xFAD mice. (B) Immunohistochemistry for amyloid-β in cerebral cortex, hippocampus and subiculum and (C) amyloid-β plaque load in cerebral cortex (Cx), hippocampus (HP) and subiculum (Sub.) after intranasal delivery of hNGFp. Scale bars are representative of mean ± SD (n = 8 per group). (D) Immunohistochemistry for amyloid-β in cerebral cortex after BDNF treatment. (E) Amyloid-β plaque load in the cortex after BDNF treatment (left) and Y-maze test (right) after BDNF intranasal treatment (n = 6 per group). (F and G) Sprouting of cholinergic fibres in the NBM after intranasal treatment with BDNF. Scale bars in B = 200 µm; D = 150 µm; F = 100 µm. Scale bars are representative of mean ± SD. WT = wild-type. *P < 0.05; **P < 0.001; ***P < 0.0001.